Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigatorSecond site, Regional…